South-Central Section of the American Urological Association SCS AUA 2024

REVIEW UroToday

Viewing 1-15 of 15 articles

SCS AUA 2024: Bladder Cancer Recurrence Analysis in Veterans and Outcomes (BRAVO): White Light Versus Blue Light Cystoscopy Outcomes Among NMIBC Patients in an Equal Access Setting

SCS AUA 2024: Exposures and Bladder Cancer Risk Among Military Veterans: A Systemic Review and Meta-Analysis

SCS AUA 2024: Indications and Outcomes for Ablation Therapy in Renal Masses

SCS AUA 2024: Indications and Outcomes for Radiation Therapy in Renal Masses

SCS AUA 2024: High Risk NMIBC Treatment: The Case for Radical Cystectomy

SCS AUA 2024: High Risk NMIBC Treatment: The Case for Bladder Sparing Therapy

SCS AUA 2024: The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist

SCS AUA 2024: BCG Will Always Be the First Line: Yes

SCS AUA 2024: BCG Shortage – An End in Sight?

SCS AUA 2024: Emerging Treatments for NMIBC

SCS AUA 2024: Clinical Trial Updates for Treatment of Metastatic Prostate Cancer

SCS AUA 2024: Focal Therapy in Prostate Cancer

SCS AUA 2024: Transitioning Men to Watchful Waiting

SCS AUA 2024: Active Surveillance for Low Volume Gleason Grade Group 2 Disease: Con

SCS AUA 2024: Active Surveillance for Intermediate Risk Prostate Cancer